Effect of intrafraction adaptation on PTV margins for MRI guided online adaptive radiotherapy for rectal cancer

Abstract

Purpose

To determine PTV margins for intrafraction motion in MRI-guided online adaptive radiotherapy for rectal cancer and the potential benefit of performing a 2nd adaptation prior to irradiation.

Methods

Thirty patients with rectal cancer received radiotherapy on a 1.5 T MR-Linac. On T2-weighted images for adaptation (MRI_adapt), verification prior to (MRI_ver) and after irradiation (MRI_post) of 5 treatment fractions per patient, the primary tumor GTV (GTV_prim) and mesorectum CTV (CTV_meso) were delineated. The structures on MRI_adapt were expanded to corresponding PTVs. We determined the required expansion margins such that on average over 5 fractions, 98% of CTV_meso and 95% of GTV_prim on MRI_post was covered in 90% of the patients. Furthermore, we studied the benefit of an additional adaptation, just prior to irradiation, by evaluating the coverage between the structures on MRI_ver and MRI_post. A threshold to assess the need for a secondary adaptation was determined by considering the overlap between MRI_adapt and MRI_ver.

Results

PTV margins for intrafraction motion without 2nd adaptation were 6.4 mm in the anterior direction and 4.0 mm in all other directions for CTV_meso and 5.0 mm isotropically for GTV_prim. A 2nd adaptation, applied for all fractions where the motion between MRI_adapt and MRI_ver exceeded 1 mm (36% of the fractions) would result in a reduction of the PTV_meso margin to 3.2 mm/2.0 mm. For PTV_prim a margin reduction to 3.5 mm is feasible when a 2nd adaptation is performed in fractions where the motion exceeded 4 mm (17% of the fractions).

Conclusion

We studied the potential benefit of intrafraction motion monitoring and a 2nd adaptation to reduce PTV margins in online adaptive MRIgRT in rectal cancer. Performing 2nd adaptations immediately after online replanning when motion exceeded 1 mm and 4 mm for CTV_meso and GTV_prim respectively, could result in a 30–50% margin reduction with limited reduction of dose to the bowel.